ANI Pharma Files 8-K on Operations & Financial Condition

TL;DR

**ANI Pharma just dropped an 8-K on its financials, keep an eye out for details.**

AI Summary

ANI Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD disclosure. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into the company's recent financial activities, potentially influencing stock valuation and investment decisions.

Why It Matters

This filing provides an update on ANI Pharmaceuticals' financial health, which is essential for investors to assess the company's performance and make informed decisions about buying, holding, or selling its stock.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate high-risk events.

Analyst Insight

Investors should look for subsequent filings or press releases that provide the specific details of the 'Results of Operations and Financial Condition' mentioned in this 8-K to fully understand the company's performance.

Key Numbers

• January 8, 2024 — Date of Report (The earliest event reported in this 8-K filing.)
• 001-31812 — Commission File Number (Unique identifier for ANI Pharmaceuticals, Inc. with the SEC.)
• 58-2301143 — I.R.S. Employer Identification No. (Tax identification number for ANI Pharmaceuticals, Inc.)

Key Players & Entities

• ANI PHARMACEUTICALS INC (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for ANI Pharmaceuticals, Inc.
• Nasdaq Stock Market (company) — exchange where ANI Pharmaceuticals' Common Stock is registered
• 001-31812 (dollar_amount) — Commission File Number for ANI Pharmaceuticals, Inc.
• 58-2301143 (dollar_amount) — I.R.S. Employer Identification No. for ANI Pharmaceuticals, Inc.
• 210 Main Street West Baudette , Minnesota 56623 (company) — address of principal executive offices for ANI Pharmaceuticals, Inc.
• (218) 634-3500 (dollar_amount) — registrant's telephone number
• ANIP (company) — trading symbol for ANI Pharmaceuticals, Inc. Common Stock

Forward-Looking Statements

• ANI Pharmaceuticals will release more detailed financial results soon. (ANI PHARMACEUTICALS INC) — high confidence, target: 2024-03-31

FAQ

Filing Documents

• ani-20240108.htm (8-K) — 30KB
• exhibit991investordeckja.htm (EX-99.1) — 30KB
• exhibit991investordeckja001.jpg (GRAPHIC) — 57KB
• exhibit991investordeckja002.jpg (GRAPHIC) — 301KB
• exhibit991investordeckja003.jpg (GRAPHIC) — 116KB
• exhibit991investordeckja004.jpg (GRAPHIC) — 118KB
• exhibit991investordeckja005.jpg (GRAPHIC) — 103KB
• exhibit991investordeckja006.jpg (GRAPHIC) — 78KB
• exhibit991investordeckja007.jpg (GRAPHIC) — 90KB
• exhibit991investordeckja008.jpg (GRAPHIC) — 155KB
• exhibit991investordeckja009.jpg (GRAPHIC) — 106KB
• exhibit991investordeckja010.jpg (GRAPHIC) — 104KB
• exhibit991investordeckja011.jpg (GRAPHIC) — 142KB
• exhibit991investordeckja012.jpg (GRAPHIC) — 161KB
• exhibit991investordeckja013.jpg (GRAPHIC) — 151KB
• exhibit991investordeckja014.jpg (GRAPHIC) — 142KB
• exhibit991investordeckja015.jpg (GRAPHIC) — 124KB
• exhibit991investordeckja016.jpg (GRAPHIC) — 57KB
• exhibit991investordeckja017.jpg (GRAPHIC) — 117KB
• exhibit991investordeckja018.jpg (GRAPHIC) — 181KB
• 0001023024-24-000002.txt ( ) — 3368KB
• ani-20240108.xsd (EX-101.SCH) — 2KB
• ani-20240108_lab.xml (EX-101.LAB) — 23KB
• ani-20240108_pre.xml (EX-101.PRE) — 12KB
• ani-20240108_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On January 8, 2024, members of ANI Pharmaceuticals, Inc.'s (the "Company") senior management team met with investors at the J.P. Morgan Healthcare Conference and provided an updated investor presentation. The Company will use the updated presentation in various meetings with investors from time to time. A copy of the presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*

01

Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*

01 Exhibits

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated January 2 024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR